×
Y-mAbs Therapeutics Income Taxes 2017-2025 | YMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Y-mAbs Therapeutics income taxes from 2017 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Y-mAbs Therapeutics Income Taxes 2017-2025 | YMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Y-mAbs Therapeutics income taxes from 2017 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Amgen (AMGN)
$149.1B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
GSK (GSK)
$74.1B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Illumina (ILMN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B